← Back to Screener
Relay Therapeutics, Inc. Common Stock (RLAY)
Price$13.52
Value ScoreF
Growth ScoreD
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)62.78%
Price vs S&P 500 (4W)5.97%
VGM Score46.84
Market Capitalization$2.95B
All Metrics
Book Value / Share (Quarterly)$3.39
P/TBV (Annual)2.59x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)123.25%
Cash Flow / Share (Quarterly)$-1.13
Price vs S&P 500 (YTD)51.65%
Net Profit Margin (TTM)-1859.66%
EPS (TTM)$-1.56
10-Day Avg Trading Volume4.75M
EPS Excl Extra (TTM)$-1.56
Revenue Growth (5Y)-28.58%
EPS (Annual)$-1.61
ROI (Annual)-48.76%
Net Profit Margin (5Y Avg)-7914.86%
Cash / Share (Quarterly)$3.39
Revenue Growth QoQ (YoY)-60.93%
ROA (Last FY)-44.50%
Revenue Growth TTM (YoY)39.04%
EBITD / Share (TTM)$-1.69
ROE (5Y Avg)-41.75%
Operating Margin (TTM)-2023.67%
Cash Flow / Share (Annual)$-1.36
P/B Ratio4.59x
P/B Ratio (Quarterly)2.77x
Net Income / Employee (Annual)$-1,440,000
EV / Revenue (TTM)256.81x
ROA (TTM)-40.11%
EPS Incl Extra (Annual)$-1.61
Current Ratio (Annual)22.61x
Quick Ratio (Quarterly)21.73x
3-Month Avg Trading Volume3.38M
52-Week Price Return317.28%
Revenue / Employee (TTM)$55,600
Tangible BV / Share (Quarterly)$3.26
P/S Ratio (Annual)191.90x
Asset Turnover (Annual)0.02x
52-Week High$17.47
Operating Margin (5Y Avg)-8175.41%
EPS Excl Extra (Annual)$-1.61
CapEx CAGR (5Y)-26.64%
26-Week Price Return70.71%
Quick Ratio (Annual)21.91x
13-Week Price Return40.25%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)22.13x
Enterprise Value$2.74B
Revenue / Share Growth (5Y)-37.24%
Asset Turnover (TTM)0.02x
Book Value / Share Growth (5Y)-17.42%
Revenue / Employee (Annual)$80,000
Pretax Margin (Annual)-1800.58%
Cash / Share (Annual)$3.19
3-Month Return Std Dev74.29%
Net Income / Employee (TTM)$-1,420,300
ROE (Last FY)-48.76%
EPS Basic Excl Extra (Annual)$-1.61
Receivables Turnover (TTM)19.65x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.56
Receivables Turnover (Annual)9.83x
ROI (TTM)-43.94%
P/S Ratio (TTM)275.97x
Pretax Margin (5Y Avg)-7914.86%
Revenue / Share (Annual)$0.09
Tangible BV / Share (Annual)$3.26
Price vs S&P 500 (52W)292.92%
Year-to-Date Return59.81%
5-Day Price Return-5.19%
EPS Normalized (Annual)$-1.61
ROA (5Y Avg)-37.25%
Net Profit Margin (Annual)-1800.58%
Month-to-Date Return-3.77%
Cash Flow / Share (TTM)$-2.64
EBITD / Share (Annual)$-1.74
Operating Margin (Annual)-1971.59%
ROI (5Y Avg)-41.75%
EPS Basic Excl Extra (TTM)$-1.56
P/TBV (Quarterly)2.59x
P/B Ratio (Annual)2.59x
Pretax Margin (TTM)-1859.66%
Book Value / Share (Annual)$3.26
Price vs S&P 500 (13W)31.99%
Beta1.72x
Revenue / Share (TTM)$0.06
ROE (TTM)-43.94%
52-Week Low$2.98
vGradeF
gGradeD
mGradeA
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.41est. -0.38
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.39
4.39
4.39
4.32
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RLAYRelay Therapeutics, Inc. Common Stock | F | D | A | $13.52 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Relay Therapeutics is a clinical-stage precision medicine company using its proprietary Dynamo platform—which combines computational and experimental approaches—to target difficult drug-protein interactions in precision oncology and genetic disease. The company is advancing a pipeline of candidates including RLY-8186, RLY-2608, and RLY-4008.